Circulating IL‐6 has been reported to be a strong independent marker correlated to increased mortality in several pathologies.[46, 47] Furthermore, high IL‐6 was also linked to fatalities in COVID‐19 patients.[48, 49] To mitigate Spike protein‐mediated thrombosis, we used antibody anti‐IL6 in the microfluidic platform to reverse the cytokine‐mediated blood coagulation. Here, IL6 is linked to COVID-19.